Telesis Bio Statistics
Share Statistics
Telesis Bio has 1.78M shares outstanding. The number of shares has increased by -94.08% in one year.
| Shares Outstanding | 1.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.34M |
| Failed to Deliver (FTD) Shares | 12 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 29.70K, so 1.67% of the outstanding shares have been sold short.
| Short Interest | 29.70K |
| Short % of Shares Out | 1.67% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 0.42 |
Valuation Ratios
The PE ratio is -79.8 and the forward PE ratio is -0.05.
| PE Ratio | -79.8 |
| Forward PE | -0.05 |
| PS Ratio | 138.45 |
| Forward PS | null |
| PB Ratio | 128.94 |
| P/FCF Ratio | -103.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Telesis Bio Inc. has an Enterprise Value (EV) of 44.55M.
| EV / Earnings | -0.93 |
| EV / Sales | 1.62 |
| EV / EBITDA | -1.1 |
| EV / EBIT | -0.96 |
| EV / FCF | -1.22 |
Financial Position
The company has a current ratio of 3.71, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.71 |
| Quick Ratio | 3.22 |
| Debt / Equity | 0.18 |
| Total Debt / Capitalization | 15.14 |
| Cash Flow / Debt | -6.58 |
| Interest Coverage | -14.99 |
Financial Efficiency
Return on equity (ROE) is -1.62% and return on capital (ROIC) is -72.85%.
| Return on Equity (ROE) | -1.62% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -72.85% |
| Revenue Per Employee | 200.80K |
| Profits Per Employee | -348.35K |
| Employee Count | 137 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.62 |
Taxes
| Income Tax | 24.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -99.7% in the last 52 weeks. The beta is 1.76, so Telesis Bio 's price volatility has been higher than the market average.
| Beta | 1.76 |
| 52-Week Price Change | -99.7% |
| 50-Day Moving Average | 0.7 |
| 200-Day Moving Average | 19.92 |
| Relative Strength Index (RSI) | 43.98 |
| Average Volume (20 Days) | 7.68K |
Income Statement
In the last 12 months, Telesis Bio had revenue of 27.51M and earned -47.72M in profits. Earnings per share was -1.64.
| Revenue | 27.51M |
| Gross Profit | 16.95M |
| Operating Income | -46.54M |
| Net Income | -47.72M |
| EBITDA | -40.49M |
| EBIT | -46.54M |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 1.57M in cash and 34.38M in debt, giving a net cash position of -32.81M.
| Cash & Cash Equivalents | 1.57M |
| Total Debt | 34.38M |
| Net Cash | -32.81M |
| Retained Earnings | -161.47M |
| Total Assets | 24.74M |
| Working Capital | 1.49M |
Cash Flow
In the last 12 months, operating cash flow was -34.67M and capital expenditures -1.98M, giving a free cash flow of -36.65M.
| Operating Cash Flow | -34.67M |
| Capital Expenditures | -1.98M |
| Free Cash Flow | -36.65M |
| FCF Per Share | -1.23 |
Margins
Gross margin is 61.62%, with operating and profit margins of -169.18% and -173.49%.
| Gross Margin | 61.62% |
| Operating Margin | -169.18% |
| Pretax Margin | -173.4% |
| Profit Margin | -173.49% |
| EBITDA Margin | -147.2% |
| EBIT Margin | -169.18% |
| FCF Margin | -133.22% |
Dividends & Yields
TBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -496.97% |
| FCF Yield | -6238.34% |
Analyst Forecast
Currently there are no analyst rating for TBIO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 9, 2024. It was a backward split with a ratio of 1:18.
| Last Split Date | May 9, 2024 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -14.23 |
| Piotroski F-Score | 3 |